Zilovertamab vedotin

• Target :

  Apoptosis|||Antibody-Drug Conjugates (ADCs)

• Related Pathways :

  Antibody-drug Conjugate/ADC Related|||Apoptosis

• Bioactivity :

  Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate composed of the humanized monoclonal antibody zilovertamab linked to the anti-microtubule cytotoxin monomethyl auristatin E (MMAE) . Upon binding to ROR1 on tumor cells, it is rapidly internalized and directed to lysosomes for cleavage, releasing MMAE and inducing apoptosis in targeted cells. Zilovertamab vedotin has potential applications in cancer research [1].

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C